Coherus Oncology (CHRS) Change in Acquisitions & Divestments (2017 - 2026)

Coherus Oncology has disclosed Change in Acquisitions & Divestments across 9 years of filings, most recently posting $38.1 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $38.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $55.5 million (changed N/A YoY), and the FY2025 annual result was $21.5 million, up 246.16% from the prior year.
• Change in Acquisitions & Divestments came in at $38.1 million for Q1 2026 at Coherus Oncology, up from $19.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $47.2 million in Q2 2023 to a low of -$94.9 million in Q4 2023.
• The 4-year median for Change in Acquisitions & Divestments is $17.5 million (2023), against an average of $8.6 million.
• Across the five-year window, Change in Acquisitions & Divestments plunged 94.73% in 2024 and jumped 896.3% in 2025, its largest moves.
• Coherus Oncology's Change in Acquisitions & Divestments stood at -$94.9 million in 2023, then surged by 97.38% to -$2.5 million in 2024, then surged by 896.3% to $19.8 million in 2025, then soared by 92.48% to $38.1 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $38.1 million (Q1 2026), $19.8 million (Q4 2025), and -$2.5 million (Q4 2024), per Business Quant data.